AWM
VTYX

Avior Wealth Management’s Ventyx Biosciences VTYX Stock Holding History

Avior Wealth Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9
Closed -$49 – 3716
2024
Q1 		$49 Buy
+9
New +$41 ﹤0.01% 3474

Other funds holding VTYX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Avior Wealth Management's VTYX Position: Q2 2024 in Review

Avior Wealth Management sold out of Ventyx Biosciences (VTYX) in Q2 2024, closing a stake of 9 shares — an estimated $49 sold.

Avior Wealth Management first reported a position in VTYX in Q1 2024 and held it in 1 quarter. The position peaked at $49 in Q1 2024. 117 funds tracked by Wall St. Rank hold VTYX as of Q2 2024.

  • Avior Wealth Management reported no remaining Ventyx Biosciences position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 9 Ventyx Biosciences shares in Q2 2024, an estimated $49.
  • Avior Wealth Management first reported a position in Ventyx Biosciences in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Ventyx Biosciences position peaked at $49 in Q1 2024.
  • 117 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.